Catalyst

Slingshot members are tracking this event:

FDA Grants Orphan Drug Designation to Biomarin's BMN-270 for Hemophilia A

Source Link:
http://investors.bmrn.com/releasedetail.cfm?ReleaseID=958288

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMRN
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details BMN 270 is an AAV 5 factor VIII vector, designed to restore factor VIII plasma concentrations, essential for blood clotting in patients with hemophilia A.   BMN-270 is currently in a phase 1/2 study of up to 12 patients to test efficacy and safety of BMN-270.
http://investors.bmr...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 01, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Orphan Drug Designation, Bmn-270, Fda, Hemophilia A
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.